HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations.

Abstract
Sulindac and other NSAIDs have been widely studied as potential chemopreventive agents for colon cancer. Short-term studies have shown adenomatous polyps to regress in patients with familial adenomatous polyposis (FAP). In this study the effect of sulindac on cancer as an endpoint was evaluated in ApcMin mice, a preclinical model of FAP with an Apc mutation in codon 850 that leads to gastrointestinal adenomas and carcinomas. Three groups of mice were studied all of which were fed AIN-76A diet: one group was fed AIN-76A diet alone, a second group received sulindac 200 p.p.m. premixed in the diet and a third group received sulindac 180 p.p.m. added in drinking water. ApcMin mice were killed 9 weeks after feeding was initiated. Mice receiving sulindac developed fewer tumors in the intestine overall; the major decrease in tumor development after sulindac was seen in the small intestine regardless of route of administration. In the large intestine, however, sulindac significantly increased the incidence, multiplicity and volume of tumors in the colon of ApcMin mice, a regional response to sulindac differing from previous reports. Quantitative measurements of apoptosis, Bax and Bcl-xL protein expression in the ApcMin mice revealed the ratio of Bax/Bcl-xL expression and apoptosis increased in the small intestine but decreased in the cecum, consistent with the regional tumorigenesis observed after sulindac. These findings thus suggest involvement of Bax and apoptosis in tumors developing after sulindac treatment in this mouse model.
AuthorsKan Yang, Kunhua Fan, Naoto Kurihara, Hiroharu Shinozaki, Basil Rigas, Leonard Augenlicht, Levy Kopelovich, Winfried Edelmann, Raju Kucherlapati, Martin Lipkin
JournalCarcinogenesis (Carcinogenesis) Vol. 24 Issue 3 Pg. 605-11 (Mar 2003) ISSN: 0143-3334 [Print] England
PMID12663524 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Bax protein, mouse
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • bcl-2-Associated X Protein
  • Sulindac
Topics
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal (adverse effects, pharmacology)
  • Genes, APC
  • Intestinal Neoplasms (chemically induced, pathology)
  • Intestine, Large (metabolism, pathology)
  • Intestine, Small (metabolism, pathology)
  • Mice
  • Mutation
  • Proto-Oncogene Proteins (metabolism)
  • Proto-Oncogene Proteins c-bcl-2
  • Sulindac (adverse effects, pharmacology)
  • bcl-2-Associated X Protein

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: